Hexarelin vs IGF-1 LR3
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Examorelin, HEX
Hexarelin is a synthetic six-amino-acid peptide (a growth hormone-releasing peptide, or GHRP) that pushes the pituitary to release growth hormone. What makes it more interesting than its cousins is a second job: it binds a receptor in heart tissue and appears to protect the heart, an effect that does not depend on growth hormone at all. It is a research compound, not an approved drug, and almost all of the heart data is from animals.
Also: Long R3 IGF-1, LR3
IGF-1 LR3 is a modified version of insulin-like growth factor 1, engineered to last far longer in the body than the natural hormone. It is popular in physique circles and it is worth being blunt about the evidence: there are effectively no human clinical trials of this specific analog. Everything below the mechanism section is preclinical work, laboratory use, or community reporting.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Hexarelin has stronger research evidence (Human Trials) compared to IGF-1 LR3 (Preclinical).
Detailed Comparison
| Attribute | Hexarelin | IGF-1 LR3 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Hexarelin acts through two different receptors, which is the key to understanding it. The first is the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor in the pituitary, which is how it triggers growth hormone release. The second is CD36, a scavenger receptor found on heart muscle cells and small blood vessels, and this is where its cardioprotective story lives. Activating CD36 in the heart has been shown to improve coronary flow and protect heart tissue from ischemia (low oxygen) and reperfusion injury, and crucially these effects still happen in growth-hormone-deficient animals, proving the heart benefit is separate from the GH benefit. | Natural IGF-1 is almost entirely bound up by IGF binding proteins in circulation, which controls how much is active and gives it a half-life measured in minutes. LR3 makes two changes: an arginine substitution at position 3, and a 13-amino-acid extension on the N-terminus. Together these dramatically reduce binding-protein affinity, so far more of the molecule stays free and active, extending the functional half-life to something on the order of a day rather than minutes. Once free, it activates the IGF-1 receptor, driving protein synthesis, satellite cell activation and cell proliferation in muscle. That same lack of binding-protein regulation is the reason for caution: binding proteins are a control mechanism, and removing the control is the point of the drug and also its main risk. |
| Common Dosing | 100-200 mcg 2-3x daily 2-3x daily | 20-50 mcg daily Once daily |
| Administration | Subcutaneous injection | Subcutaneous injection. Because of the hypoglycemia risk, timing relative to carbohydrate intake is the main practical consideration reported. |
| Typical Duration | 4-8 weeks (desensitization occurs) | Community cycles are typically reported as 4-6 weeks, on the reasoning that receptor downregulation follows longer use |
| Best Time to Take | Morning and before bed (fasted) | With or near a carbohydrate-containing meal |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The growth hormone-releasing effect of hexarelin is well established in humans from older endocrine research, but the exciting cardiovascular claims are still mostly preclinical. The landmark mechanistic work (Circulation Research, 2002) identified CD36 as the receptor through which growth hormone-releasing peptides act on the heart, and follow-up rodent studies showed hexarelin improves left ventricular function and protects cardiomyocytes from ischemia-reperfusion injury, in one case through interleukin-1 signaling (2017). A 2014 review in the Annals of the New York Academy of Sciences and a 2017 PMC review both lay out a plausible cardioprotective case. But here is the honest part: there are no large modern human trials showing hexarelin treats or prevents heart disease in people, and a known limitation is rapid tolerance, the GH response fades with continued use. So the cardiac angle is genuinely interesting biology, not an established therapy. | IGF-1 LR3 was developed as a cell culture reagent, and that remains its principal legitimate use: it is sold to laboratories to promote cell growth in bioreactors. There are no published randomized human trials of IGF-1 LR3 for muscle growth, body composition or performance. The animal and in vitro work does show what you would expect, increased protein synthesis and muscle cell proliferation, and there is a genuine human literature on recombinant IGF-1 (mecasermin) for severe IGF-1 deficiency, but mecasermin is a different molecule with different pharmacokinetics and its trial data should not be read across. The two consistent safety themes in the underlying biology are hypoglycemia, because IGF-1 has meaningful cross-reactivity with the insulin receptor, and the theoretical concern that chronically elevated IGF-1 signalling promotes growth of tissue you did not intend to grow, including existing tumors. |
Frequently Asked Questions: Hexarelin vs IGF-1 LR3
What is the difference between Hexarelin and IGF-1 LR3?
Hexarelin is a growth hormone peptide that hexarelin is a synthetic six-amino-acid peptide (a growth hormone-releasing peptide, or ghrp) that pushes the pituitary to release growth hormone. what makes it more interesting than its cousins is a second job: it binds a receptor in heart tissue and appears to protect the heart, an effect that does not depend on growth hormone at all. it is a research compound, not an approved drug, and almost all of the heart data is from animals. IGF-1 LR3 is a growth hormone peptide that igf-1 lr3 is a modified version of insulin-like growth factor 1, engineered to last far longer in the body than the natural hormone. it is popular in physique circles and it is worth being blunt about the evidence: there are effectively no human clinical trials of this specific analog. everything below the mechanism section is preclinical work, laboratory use, or community reporting. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Hexarelin or IGF-1 LR3?
Neither is universally "better" - the choice depends on your specific goals. Hexarelin is typically used for growth hormone purposes, while IGF-1 LR3 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Hexarelin and IGF-1 LR3 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Hexarelin and IGF-1 LR3 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.